The U.S. Drug Enforcement Administration says there is a nationwide spike in fentanyl-related mass overdose events involving three or more overdoses occurring around the same time at the same location.
TUCSON, Ariz. — The United States Drug Enforcement Administration says there is a nationwide spike in fentanyl-related mass overdose events involving three or more overdoses occurring around the same time at the same location.
The overdoses happen when unsuspecting victims think they are consuming cocaine, but it is really fentanyl. In the past two months, there have been over seven confirmed mass overdose events across the United States resulting in 58 overdoses and 29 overdose deaths says the DEA.----
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Santa Clara County, San Jose cracking down on illegal use, distribution of drug 'whip-its''Many kids think that it's safe, so they're looking for a high that they think is safe... But it's not safe. So they're fooled by it and it is addictive.'
Read more »
Medicare Considers Cutting Premiums After Limiting Alzheimer’s Drug CoverageMedicare said Thursday it’s considering a cut in enrollee premiums after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs.
Read more »
Medicare limits coverage of controversial Alzheimer's drug to those in clinical trialsMedicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
Read more »
Medicare Weighs Premium Cut After Limiting Alzheimer's DrugMedicare said Thursday it's considering a cut in enrollee premiums after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer's drug projected to drive up program costs.
Read more »
Medicare Will Only Cover New Alzheimer’s Drug in TrialsFederal officials have made their final decision: Medicare will only pay for patients to get the new Alzheimer's drug aducanumab (Aduhelm) if the patients are participating in clinical trials.
Read more »
Medicare limits payments for new Alzheimer’s drug to clinical trialsThe federal government affirmed its plan to limit coverage for a costly new medication for Alzheimer’s disease, restricting it to Medicare patients enrolled in clinical trials.
Read more »